Sofia, Bulgaria, December 20, 2024 – In accordance with the requirements of Art. 100t of the LPOS, Sopharma AD (SFA: Bulgarian Stock Exchange AD, SPH: Warsaw Stock Exchange) hereby informs that in order to ensure operational opportunities for growth and increase sales on the traditional markets where the Company operates, the Board of Directors has decided to make an additional contribution to its subsidiary “Sopharma Rus” OOO in the amount of EUR 12.3 million, not increasing the capital.

Sofia, Bulgaria, December 19, 2024 - Pursuant to the requirements of Article 100t of the LPOS and in conjunction with Article 114, par. 9 of the LPOS, "Sopharma" AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) hereby informs, that The Board of Directors, at its meeting held on December 19, 2024, in accordance with the requirements of art. 114, para 2 of the LPOS and in accordance with the Group's strategy for optimization and focus on health related activities, approved the conclusion of the following transaction:

Sofia, Bulgaria December 19, 2024 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that for November 2024 the Company recorded a decrease in sales of 10% compared to the same month of the previous year, incl. remain the same in domestic sales and 17% decrease in export sales.

For the period from the beginning of 2024, the Company recorded a decrease in sales of 8%, incl. 4% increase of domestic sales and 14% decrease in export sales.